Leerink Partnrs Has Bearish Forecast for Danaher Q4 Earnings

Danaher Co. (NYSE:DHR) – Equities research analysts at Leerink Partnrs lowered their Q4 2024 EPS estimates for Danaher in a report released on Tuesday, October 22nd. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will earn $2.15 per share for the quarter, down from their previous forecast of $2.39. The consensus estimate for Danaher’s current full-year earnings is $7.59 per share.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the firm posted $2.02 EPS. The company’s revenue was up 3.1% on a year-over-year basis.

A number of other research analysts also recently issued reports on DHR. Evercore ISI raised their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Bank of America raised their target price on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Barclays reduced their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research report on Wednesday. The Goldman Sachs Group raised their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Finally, KeyCorp upped their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $287.28.

Danaher Stock Down 3.2 %

DHR opened at $247.88 on Thursday. Danaher has a one year low of $182.09 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $183.60 billion, a P/E ratio of 42.03, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The business’s 50-day simple moving average is $270.43 and its 200-day simple moving average is $260.43.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is presently 18.31%.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the completion of the sale, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,059 shares of company stock worth $8,400,897. 11.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Danaher

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Swedbank AB acquired a new position in shares of Danaher during the 1st quarter worth approximately $676,545,000. TD Asset Management Inc lifted its stake in Danaher by 99.0% in the 2nd quarter. TD Asset Management Inc now owns 1,358,706 shares of the conglomerate’s stock valued at $339,473,000 after buying an additional 675,952 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Danaher by 22.7% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares during the last quarter. Finally, International Assets Investment Management LLC increased its position in Danaher by 40,196.5% during the third quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after buying an additional 428,897 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.